Compare Enphase Energy Inc (ENPH) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Eli Lilly And Co — how do they compare? Enphase Energy Inc trades at $33.2 (market cap $4.35B), while Eli Lilly And Co trades at $1,167.63 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 239.1× Enphase Energy Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Eli Lilly And Co for 93 Days on average.
| ENPH | LLY | |
|---|---|---|
Market Cap | $4.35B | $1.04T |
Volume | 5,068,595 | 3,064,878 |
Sector | Energy | Health |
52-Week High | $72.33 | $1.28K |
52-Week Low | $26.12 | $799.57 |
Typical Hold Time | 72 Days | 93 Days |
Enterprise Value | $3.99B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENPH trades at $33.50, down 1.21% on the day, with a bearish technical signal and mixed earnings history. Revenue declined to $1.47B in 2025 from $2.3B in 2023, though net income margin improved to 11.68%. Recent news includes product approvals and manufacturing milestones for AI data centers, but the stock faces pressure from high borrowing costs impacting the solar sector. The company maintains solid liquidity with $1.62B in cash, but debt levels remain elevated.
The outlook is cautious; analyst consensus is a Buy with a $42.90 price target, but recent earnings misses and sector headwinds pose risks. Upside depends on execution in AI infrastructure and EV charging, while competition and interest rate sensitivity are key concerns. The stock offers potential for recovery if operational trends stabilize.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
